ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
 PMID: 21685536       2011       Antiviral therapy
Abstract: The DRV-2009 score V11I+L33F+R41K+I47V+2*I50V+2*I54M+K55R+D60E+L74P+L76V+N88D+2*L89V-L10I/V-I13V-G16E-G48V-F53I/L-I62V-I66F-V77I (<0 indicating susceptibility, 0-1 intermediate resistance and >=2 resistance) correlated with VR in the derivation set (n=132, R=0.395; P<0.001).


  The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
 PMID: 21314993       2011       AIDS research and therapy
Table: V77I


  Differences in reversion of resistance mutations to wild-type under structured treatment interruption and related increase in replication capacity.
 PMID: 21297946       2011       PloS one
Introduction: The authors reported a faster rate of reversion for primary resistance mutations (K70R, M184I/V, T215Y/F in RT, and D30N, M46I/L, V82A, L90M in PR) compared to secondary mutations (M41L, D67N, T69D/N, L210W, K219Q/E in RT and L10I/V, L63P, A71V/T, V77I in PR)


  HIV drug resistance surveillance using pooled pyrosequencing.
 PMID: 20174661       2010       PloS one
Table: V77I


  [Prevalence of primary antiretroviral resistance among HIV infected patients in Chile].
 PMID: 20919475       2010       Revista medica de Chile
Abstract: Of these, the most common were L63P/T (38 patients), L10I/V (27 patients) and V77I (26 patients).


  Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.
 PMID: 20532178       2010       PloS one
Table: V77I


  Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
 PMID: 20455467       2010       Voprosy virusologii
Abstract: According to the presence or absence of mutations V77I in protease and/or A62V in reverse transcriptase, the patients were divided into 2 study groups.
Abstract: Immunological study showed that the median CD4+, CD8+, and CD4/CD8 in the patients infected with virus variants containing mutations V77I and/or A62V were increased by 25, 20, and 16%, respectively.


  Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
 PMID: 20377421       2010       AIDS research and human retroviruses
Abstract: Forty (97.6%) of 41 samples were of subtype A, former Soviet Union variant (A(FSU)), of which 27 (67.5%) clustered with the subvariant containing the V77I substitution in protease (V77I(PR)).
Abstract: The results, therefore, show the relationship of the HIV-1 epidemic in Dagestan with that of other areas of Russia and of neighboring countries, and reveal the spread of the A(FSU) V77I(PR) variant in the North Caucasus area.


  Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.
 PMID: 19583845       2009       BMC infectious diseases
Table: V77I


  HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.
 PMID: 19578237       2009       Antiviral therapy
Discussion: The impact of these on viral drug susceptibility is uncertain, but many, including L10I/V, K20R, M36I, L63P, A71V/T and V77I, are not expected to cause major drug resistance.



Browser Board

 Co-occurred Entities




   Filtrator